Jens Köllermann

Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer

J. Köllermann, K. Miller, M. Schrader, 2006, British Journal of Cancer.

Nondetected Tumor (pT0) after Prolonged, Neoadjuvant Treatment of Localized Prostatic Carcinoma

J. Köllermann, U. Feek, B. Helpap, 2000, European Urology.

Patient and tumor characteristics of histological subtypes of renal cell carcinoma and its risk of upstaging to ≥pT3.

L. Kluth, S. Bernatz, P. Mandel, 2023, Urologic oncology.

Why we should not routinely apply irreversible electroporation as an alternative curative treatment modality for localized prostate cancer at this stage

B. Hadaschik, H. Schlemmer, J. Köllermann, 2016, World Journal of Urology.

Activating BRAF gene mutations are uncommon in hormone refractory prostate cancer in Caucasian patients.

G. Sauter, J. Köllermann, T. Schlomm, 2010, Oncology letters.

Epigenetic profiling of prostate cancer reveals potential prognostic signatures

Ian G. Reddin, S. Bernatz, S. Mahmoudi, 2024, Journal of cancer research and clinical oncology.

Histopathological, Molecular and Clinical Profiling of Lymphoepithelioma-Like Carcinoma of the Bladder (LELC-B)

S. Banek, Jan Jeroch, P. Wild, 2024, Modern Pathology.